A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Phase 2
100
about 2.1 years
65+
7 sites in NJ, NY
Why this study is shown
What this study is about
This trial is testing whether allogeneic hematopoietic stem cell transplant, azacitidine and venetoclax, or maintenance therapy with azacitidine and venetoclax is more effective at preventing acute myeloid leukemia (AML) from returning.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine (AZA)
- 2.Take Venetoclax
- 3.Undergo Allogeneic hematopoietic stem cell transplantation
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, venetoclax
injection, subcutaneous, oral
Primary: 1-year Relapse free survival (RFS)
Secondary: Overall survival (OS)
Oncology